Richter Gedeon Vegyeszeti Gyár Nyilvánosan Muködo Rt : Extraordinary Information

Richter acquires HELM's entire stake in Richter-Helm BioTec and

Richter-Helm BioLogics joint ventures in Germany

Budapest, 6 March 2024 - Gedeon Richter Plc. ("Richter") announces today that it has signed an agreement with HELM AG, a Germany-based stock corporation ("HELM") to buy 50% stake in Richter-Helm BioTec GmbH & Co. KG ("RHT"); and 30% stake in Richter-Helm BioLogics GmbH & Co. KG. ("RHB") to become 100% owner of both companies. Under the terms of the agreement Richter will pay EUR 40.6mn for HELM's stake in RHB and EUR 71.8mn for HELM's stake in RHT. The purchase price both for RHT and RHB are due on the closure of the transaction pending the merger clearance by both the German and Hungarian competition authorities and other conditions set out in the agreement. On top of the EUR 71.8mn Richter will pay for RHT a further earnout scheme in respect of 2025-2029, subject to the performance of RHT.

RHT is the owner of a teriparatide biosimilar asset with numerous license partners globally, including STADA, Daewon, Mochida and Richter itself. The Terrosa® brand is currently the key product within the Biotechnology Business Unit of Richter with a total of EUR 56.8mn booked sales in 2023. Total global teriparatide sales by all RHT licensees reached close to EUR 125mn in 2023.

RHB is a northern-Germany based leading microbial CDMO company with three sites, an experienced management, more than 300 employees and around EUR 60mn annual revenues. RHB is expected to complete in 2024 a major, close to EUR 100mn investment to significantly expand its manufacturing capacity enabling further growth and strengthening its service offering to its pharmaceutical clients.

The transaction will consolidate Richter's ownership and control of the German biological assets and will further support the Biotechnology Business Unit's revenues and profitability. Given, RHB is already majority owned by Richter, integration of RHB into the biotechnology business unit is expected to be smooth.

Dr. Erik Bogsch, Director of the Biotechnology Business Unit of Richter commented on the transaction: "The German assets together with Richter's current biotechnology capability in Hungary will create a very strong biotechnology platform allowing even better service offerings in a cost-efficient way ensuring long-term value creation for Richter, and its clients and partners alike."

About Gedeon Richter Plc.

Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China, Latin America, and Australia. Having reached a market capitalization of EUR 4.3bn (USD 4.7bn) by the end of 2023, Richter's consolidated sales were approximately EUR 2.1bn (USD 2.3bn) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.

For further information:

Investors:	Róbert Réthy	[phone]
Media:	Zsuzsa Beke	[phone]